Charles River Laboratories
629 hedge funds and large institutions have $10.3B invested in Charles River Laboratories in 2024 Q3 according to their latest regulatory filings, with 66 funds opening new positions, 205 increasing their positions, 273 reducing their positions, and 97 closing their positions.
0.84% less ownership
Funds ownership: 101.73% → 100.89% (-0.84%)
3% less capital inflows, than outflows
Capital inflows: $1.52B | Capital outflows: $1.58B
6% less funds holding
Funds holding: 666 → 629 (-37)
25% less repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 273
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
32% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 97
38% less call options, than puts
Call options by funds: $59M | Put options by funds: $94.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$777M |
| 2 |
Eminence Capital
New York
|
+$209M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$106M |
| 4 |
Impactive Capital
New York City,
New York
|
+$78.2M |
| 5 |
Cooke & Bieler
Philadelphia,
Pennsylvania
|
+$62.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$177M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$107M |
| 3 |
Southpoint Capital Advisors
New York
|
-$100M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$97.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$67.2M |
CRL Hedge Fund Activity: Q3 2024 in Review
629 of the 6,985 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q3 2024, worth a combined $10.3B — down 5.2% from $10.8B a quarter earlier.
Sellers outnumbered buyers: 97 funds closed out of CRL and 66 opened new positions — a net loss of 31 holders — while 273 trimmed existing stakes and 205 added.
The largest buyer was Wellington Management Group, adding an estimated $777M. The largest seller was BlackRock, cutting an estimated $177M.
- 629 institutional investors held Charles River Laboratories (CRL) as of Q3 2024, down from 666 in Q2 2024.
- Funds reported $10.3B of Charles River Laboratories stock for Q3 2024, down 5.2% quarter-over-quarter.
- 66 funds opened new Charles River Laboratories positions in Q3 2024 and 97 closed out, a net change of -31 holders.
- The largest Charles River Laboratories buyer in Q3 2024 was Wellington Management Group, an estimated $777M added.
- The largest Charles River Laboratories seller in Q3 2024 was BlackRock, an estimated $177M sold.
Based on aggregated 13F filings for Q3 2024.